Press release
Alzheimer's Drugs Market Size Worth $9.8 Billion by 2027 | CAGR 6.21%
Alzheimer's disease (AD) is a chronic or persistent disorder that attacks the brain cells, affecting memory, thinking and behavior. Alzheimer's drugs refer to medications that help lessen symptoms, such as memory loss and confusion, for a limited time. These drugs also influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.
Covid-19 Scenario:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Download a free sample report to get a detailed overview of the report: https://www.imarcgroup.com/alzeimers-drugs-market/requestsample
Alzheimer's Drugs Market Trends:
The global Alzheimer's drugs market is primarily driven by the increasing number of people diagnosed with Alzheimer's disease. Besides this, the increasing prevalence of chronic diseases, such as diabetes, obesity, heart diseases and high blood pressure (BP), that increase the risk of Alzheimer's are contributing to the market. This is further supported by unhealthy dietary patterns, sedentary lifestyles and smoking, which are known to increase the chances of developing Alzheimer's disease. Moreover, several pharmaceutical companies are developing drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The development of these drugs is anticipated to propel market growth in the coming years.
Global Alzheimer's Drugs Market 2022-2027 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
AbbVie (NYSE: ABBV), AstraZeneca PLC (AZN), Biogen Inc. (BIIB)., Daiichi Sankyo Company, Limited (DSNKY), Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.
Ask Analyst for 10% free customized report: https://www.imarcgroup.com/alzeimers-drugs-market
The report has segmented the market on the basis of Type, Thickness, Production Process, Application and Region.
By Drug Class:
Donepezil
Galantamine
Rivastigmine
Memantine
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Stores
Others
By Region:
North America
Asia Pacific
Europe
Latin America
Middle East and Africa
Contact Us
30 N Gould St
Ste R
Sheridan, WY 82801
USA
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Drugs Market Size Worth $9.8 Billion by 2027 | CAGR 6.21% here
News-ID: 2811146 • Views: …
More Releases from IMARC Group
GCC Pet Food Market Size is Expected to Reach USD 422.9 Million By 2033 | CAGR: …
GCC Pet Food Market Overview
Market Size in 2024: USD 266.2 Million
Market Size in 2033: USD 422.9 Million
Market Growth Rate 2025-2033: 5.3%
According to IMARC Group's latest research publication, "GCC Pet Food Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", the GCC pet food market size was valued at USD 266.2 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 422.9 Million by 2033, exhibiting a…
GCC Residential Real Estate Market Size to Worth USD 147.77 Billion by 2033 | Wi …
GCC Residential Real Estate Market Overview
Market Size in 2024: USD 73.31 Billion
Market Size in 2033: USD 147.77 Billion
Market Growth Rate 2025-2033: 7.50%
According to IMARC Group's latest research publication, "GCC Residential Real Estate Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", the GCC residential real estate market size was valued at USD 73.31 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 147.77 Billion by…
GCC Drones Market Size to Surpass USD 2,005.3 Million by 2033 | With a 13.3% CAG …
GCC Drones Market Overview
Market Size in 2024: USD 588.2 Million
Market Size in 2033: USD 2,005.3 Million
Market Growth Rate 2025-2033: 13.3%
According to IMARC Group's latest research publication, "GCC Drones Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The GCC drones market size was valued at USD 588.2 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 2,005.3 Million by 2033, exhibiting a growth rate of…
Medical Imaging Market to Surpass USD 70.8 Billion by 2033, at a CAGR of 5.03%
Market Overview:
The medical imaging market is experiencing rapid growth, driven by Growing Burden of Chronic and Age-Related Diseases, Expansion of Government-Funded Health Infrastructure and Technological Advancements in Imaging Modalities. According to IMARC Group's latest research publication, "Medical Imaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The global medical imaging market size reached USD 44.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
